Vascular cognitive impairment
Conditions
Interventions
Control group:Basic treatment such as blood pressure reduction, glucose control and lipid regulation
Treatment group:On the basis of treatment, the control group was combined with pentoxifylline sustained-release tablets, 1 tablet / time (400mg / time), twice a day, 400mg~800mg daily
Sponsors
Wenzhou People Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18-80 years old; 2. Comply with the diagnosis of vascular cognitive impairment in the "Diagnosis and Treatment Standards for Vascular Cognitive Impairment (2020 Edition)"; For patients with mild to moderate vascular cognitive impairment, the MMSE scale score is 10-26 points; 3. Blood pressure< 140/90 mmHg, glycosylated hemoglobin (HbA1c) <7%, low-density lipoprotein (LDL-C) < 3.4mmol/L; 4. The patient or his/her legal representative signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who have been previously diagnosed with dementia caused by other brain diseases (such as Alzheimer's disease, dementia with Lewy bodies, dementia from frontotemporal lobe, Parkinson's disease, demyelination of the central nervous system, tumors, hydrocephalus, trauma, syphilis, AIDS, Creutzfeldt-Jakob disease, etc.); 2. Patients who have taken anti-dementia drugs (such as donepezil, rivastigmine, memantine, ginkgo biloba extract, etc.) in the past (in the past 3 months); 3. Patients with cognitive impairment or decline due to other reasons (such as severe depression, VitB12 deficiency, hypothyroidism, etc.); 4. Patients with acute myocardial infarction, severe coronary arteriosclerosis, and bleeding tendencies (such as subarachnoid hemorrhage, cerebral hemorrhage, gastrointestinal hemorrhage, extensive retinal hemorrhage, subdural hematoma, epidural hematoma); 5. Patients with severe hepatic insufficiency, severe renal insufficiency, and severe cardiac insufficiency before randomization4; 6. Those who are known to have a history of allergy to pentoxifylline and methylxanthines (such as caffeine, theophylline, aminophylline); 7. Use of drugs that affect the results of the trial during the study; 8. Pregnant, lactating and planning to become pregnant; 9. Those who are in a coma or have severe impairment of consciousness, aphasia, agnosia or deafness, which then affect expression and communication, and are unable to cooperate with the completion of follow-up; 10. Those who participated in other clinical trials within 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MMSE score change from baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| MMSE score change from baseline;EQ-5D score and its change from baseline;mRS score and its change from baseline; | — |
Countries
China
Contacts
Public ContactHua Ye
Wenzhou People Hospital
Outcome results
None listed